Jan Oldenburg, MD, PhD, presented “Results from the Norwegian Prostate Cancer Consortium (NPCC)” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Oldenburg, Jan. “Results from the Norwegian Prostate Cancer Consortium (NPCC).” October 8, 2024. Accessed Dec 2024. https://grandroundsinurology.com/results-from-the-norwegian-prostate-cancer-consortium-npcc/
Results from the Norwegian Prostate Cancer Consortium (NPCC) – Summary
Jan Oldenburg, MD, PhD, presents a detailed exploration of findings from the Norwegian Prostate Cancer Consortium, focusing on the predictive value of baseline PSA levels for prostate cancer risk and mortality. In this 10-minute presentation, Dr. Oldenburg analyzes the data from the NPCC study, revealing that PSA levels strongly correlate with long-term outcomes over an 18-year follow-up period.
Dr. Oldenburg calls for tailored screening protocols to balance early detection with minimizing unnecessary interventions. With comprehensive data and practical implications, his talk offers critical insights into PSA screening, making it an essential watch for clinicians focused on advancing prostate cancer management.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
